RadNet (RDNT) Expected to Announce Quarterly Earnings on Sunday

RadNet (NASDAQ:RDNT) is projected to issue its Q3 2026 results before the market opens on Sunday, November 8th. Analysts expect the company to announce earnings of $0.2214 per share and revenue of $639.97 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 10:30 AM ET.

RadNet (NASDAQ:RDNT) last issued its earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.09. The business had revenue of $622.72 million during the quarter, compared to analysts’ expectations of $610.87 million. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, analysts expect RadNet to post $0.49 EPS for the current fiscal year and $0.87 EPS for the next fiscal year.

RadNet Trading Down 2.6%

NASDAQ:RDNT opened at $76.00 on Friday. The company has a market cap of $5.98 billion, a P/E ratio of 166.14 and a beta of 1.42. The stock’s fifty day moving average price is $72.57 and its two-hundred day moving average price is $65.40. RadNet has a 1 year low of $50.82 and a 1 year high of $85.84. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.48 and a quick ratio of 1.48.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on RDNT. Zacks Research upgraded shares of RadNet from a “hold” rating to a “strong-buy” rating in a report on Friday, October 9th. Barclays increased their price target on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Truist Financial boosted their price target on shares of RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Raymond James Financial reissued a “strong-buy” rating on shares of RadNet in a research note on Tuesday, September 22nd. Finally, Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a report on Friday, July 31st. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, RadNet presently has an average rating of “Buy” and a consensus target price of $90.00.

About RadNet

RadNet, Inc (NASDAQ: RDNT) is an outpatient diagnostic imaging company that operates imaging centers and provides related healthcare services. Its facilities offer diagnostic radiology and imaging procedures used to help detect, diagnose, and monitor medical conditions.

The company’s services generally include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray, and other imaging procedures. RadNet also provides image-guided and interventional radiology services in selected markets, along with digital imaging, radiology, and information-technology solutions.

Founded in 1981, RadNet serves patients, physicians, hospitals, and other healthcare organizations through a network of outpatient imaging centers primarily located in the United States, including markets in California, New York, New Jersey, Maryland, and Delaware.